Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4453MR)

This product GTTS-WQ4453MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4453MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9123MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ5765MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ2277MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ514MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 47H4
GTTS-WQ14055MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ13250MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ9281MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ13945MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW